4//SEC Filing
Baum Jason 4
Accession 0001104659-25-030809
CIK 0001509745other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 9:53 PM ET
Size
11.4 KB
Accession
0001104659-25-030809
Insider Transaction Report
Form 4
Baum Jason
Chief Scientific Officer
Transactions
- Tax Payment
Common Stock
2025-03-28$0.32/sh−6,604$2,091→ 15,896 total - Exercise/Conversion
Restricted Stock Units
2025-03-28−22,500→ 0 total→ Common Stock (22,500 underlying) - Exercise/Conversion
Common Stock
2025-03-28+22,500→ 22,500 total
Footnotes (6)
- [F1]22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.
- [F2]The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.
- [F3]Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.
- [F4]The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.
- [F5]The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.
- [F6]The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.
Documents
Issuer
LEAP THERAPEUTICS, INC.
CIK 0001509745
Entity typeother
Related Parties
1- filerCIK 0001970907
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 9:53 PM ET
- Size
- 11.4 KB